For the full protocol evaluation process, see our guide to how Perfect B structures supervised peptide protocols in Doral, FL
Research indicates that tirzepatide may produce greater weight loss than semaglutide at equivalent stages, making it a preferred choice for some patients
10.1089/lrb.2019.0072 40 FarrO
Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers
It wins by owning an adjacent metabolic indication the incumbents have not closed out
Consistent supply typically indicates stable manufacturing relationships, which correlates with consistent quality
